Reconciling predicted and measured viscosity parameters in high concentration therapeutic antibody solutions
Monoclonal antibody (mAb) solution viscosity in ultra-high concentration formulations is a key developability consideration in mAb development risk mitigation strategies that has implications for downstream processing and patient safety. Predicting viscosity at therapeutically relevant concentration...
Saved in:
Main Authors: | Georgina Bethany Armstrong, Aisling Roche, William Lewis, Zahra Rattray |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2438172 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reduction of monoclonal antibody viscosity using interpretable machine learning
by: Emily K. Makowski, et al.
Published: (2024-12-01) -
Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate
by: Tobias M. Prass, et al.
Published: (2024-12-01) -
Editorial: The immune response to therapeutic antibodies
by: Michael G. Tovey, et al.
Published: (2025-02-01) -
Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01) -
Effect of NaCI solution concentration, particle size and ratio on viscosity inhibitor of porang flour
by: Mohammad Amirul Muzakki, et al.
Published: (2025-01-01)